[go: up one dir, main page]

DK0986644T3 - Preparation of erythropoietin by endogenous gene activation with viral promoters - Google Patents

Preparation of erythropoietin by endogenous gene activation with viral promoters

Info

Publication number
DK0986644T3
DK0986644T3 DK98941401T DK98941401T DK0986644T3 DK 0986644 T3 DK0986644 T3 DK 0986644T3 DK 98941401 T DK98941401 T DK 98941401T DK 98941401 T DK98941401 T DK 98941401T DK 0986644 T3 DK0986644 T3 DK 0986644T3
Authority
DK
Denmark
Prior art keywords
epo
erythropoietin
human
preparation
endogenous gene
Prior art date
Application number
DK98941401T
Other languages
Danish (da)
Inventor
Anne Stern
Michael Brandt
Konrad Honold
Hans Koll
Johannes Auer
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0986644(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/en
Priority claimed from US09/113,692 external-priority patent/US6548296B1/en
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of DK0986644T3 publication Critical patent/DK0986644T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns human cells which, owing to the activation of the endogenous human erythropoietin gene, can produce erythropoietin (EPO) in sufficient quantities and degree of purity to allow human EPO to be economically produced as a pharmaceutical preparation. The invention also concerns a process for producing such human EPO-producing cells, DNA-constructs for activating the endogenous EPO gene in human cells and a process for the large-scale production of EPO in human cells.
DK98941401T 1997-07-23 1998-07-22 Preparation of erythropoietin by endogenous gene activation with viral promoters DK0986644T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97112640 1997-07-23
DE1997153681 DE19753681A1 (en) 1997-12-03 1997-12-03 Erythropoietin composition has a highly specific activity
US09/113,692 US6548296B1 (en) 1997-07-23 1998-07-10 Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PCT/EP1998/004590 WO1999005268A1 (en) 1997-07-23 1998-07-22 Production of erythropoietin by endogenous gene activation

Publications (1)

Publication Number Publication Date
DK0986644T3 true DK0986644T3 (en) 2007-01-29

Family

ID=27217987

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98941401T DK0986644T3 (en) 1997-07-23 1998-07-22 Preparation of erythropoietin by endogenous gene activation with viral promoters

Country Status (13)

Country Link
EP (1) EP0986644B1 (en)
JP (1) JP4541539B2 (en)
CN (1) CN1151258C (en)
AT (1) ATE341625T1 (en)
AU (1) AU754619B2 (en)
BR (1) BRPI9811031B8 (en)
CA (1) CA2298015C (en)
DE (1) DE59813758D1 (en)
DK (1) DK0986644T3 (en)
ES (1) ES2273434T3 (en)
TR (1) TR200000175T2 (en)
TW (1) TW574372B (en)
WO (1) WO1999005268A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
BR9813391C1 (en) 1997-12-03 2021-05-25 Roche Diagnostics Gmbh process to produce an epo composition and process to increase the specific activity of an epo composition
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
AT409379B (en) 1999-06-02 2002-07-25 Baxter Ag MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
WO2002064085A2 (en) 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
KR100493703B1 (en) * 2001-10-30 2005-06-02 신풍제약주식회사 Recombinant Vectors Useful in Animal Cells and Expression Vectors for Preparing Erythropoietin
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2002357019A1 (en) 2001-11-28 2003-06-10 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
WO2003078959A2 (en) 2002-03-11 2003-09-25 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
EP2287288B1 (en) 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
CN100383238C (en) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2629304T3 (en) 2006-01-04 2017-08-08 Baxalta Incorporated Cell culture medium without oligopeptides
CN101062407A (en) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
EP2134862A4 (en) * 2007-03-12 2011-04-20 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETIC MICROVASCULAR COMPLICATIONS
JP5702150B2 (en) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. Modified leptin polypeptides and their use
ES2435272T3 (en) 2008-09-23 2013-12-17 F. Hoffmann-La Roche Ag Erythropoietin purification
WO2010036964A2 (en) 2008-09-26 2010-04-01 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
CN102659928B (en) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 Synthetic signal peptide and application thereof
CN102659927B (en) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 Synthetic signal peptide and application thereof
CN104059128B (en) * 2010-09-17 2016-08-03 上海凯茂生物医药有限公司 The signal peptide of a kind of synthetic and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
JPS62171696A (en) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd Production of human erythropoietin
JPS62265992A (en) * 1986-05-12 1987-11-18 Ajinomoto Co Inc Production of valuable substance using human cell
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
JPH01165393A (en) * 1987-12-21 1989-06-29 Sumitomo Chem Co Ltd Method for purifying recombinant human erythropoietin
ES2090297T5 (en) * 1989-11-06 2005-03-01 Cell Genesys, Inc. PRODUCTION OF PROTEINS THAT USE HOMOLOGICAL RECOMBINATION.
DE69031172T2 (en) * 1989-12-22 1998-03-12 Applied Research Systems Ars Holding N.V., Curacao MODIFICATION OF ENDOGENIC GENE EXPRESSION BY MEANS OF A REGULATORY ELEMENT BY MEANS OF HOMOLOGOUS RECOMBINATION
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (en) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
TW574372B (en) 2004-02-01
JP4541539B2 (en) 2010-09-08
EP0986644B1 (en) 2006-10-04
AU8978698A (en) 1999-02-16
CN1151258C (en) 2004-05-26
TR200000175T2 (en) 2001-01-22
BRPI9811031B8 (en) 2021-07-06
WO1999005268A1 (en) 1999-02-04
EP0986644A1 (en) 2000-03-22
JP2001511343A (en) 2001-08-14
AU754619B2 (en) 2002-11-21
BRPI9811031A (en) 2000-08-08
CA2298015C (en) 2015-01-27
ES2273434T3 (en) 2007-05-01
CN1265143A (en) 2000-08-30
DE59813758D1 (en) 2006-11-16
CA2298015A1 (en) 1999-02-04
BRPI9811031B1 (en) 2011-10-04
ATE341625T1 (en) 2006-10-15

Similar Documents

Publication Publication Date Title
DK0986644T3 (en) Preparation of erythropoietin by endogenous gene activation with viral promoters
EP0931162A4 (en) Production of a multimeric protein by cell fusion method
CY1111099T1 (en) Yeast Executives Producing Steroids In Autonomous Way
MY134696A (en) Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
DE60228460D1 (en) Process for the preparation and purification of erythropoietin
DE69635675D1 (en) REDUCED NEUROTROPHIC FACTOR OBTAINED FROM A GLIA CELL LINE
EP0367145A3 (en) New process for the production of l-2-amino-4(hydroxymethyl-phospinyl)-butyric acid
AU7471698A (en) Intracellular production of hepatitis c e1 and e2 truncated polypeptides
BR0115036A (en) Process for the preparation of a compound
EP1038001B8 (en) Constitutive expression of non-infectious hiv-like particles
PT835137E (en) ENCAPSULATED CELLS PRODUCING VIRAL PARTICLES
DK1015494T3 (en) Process for the preparation of catalytic antibodies
DK1346026T3 (en) Microorganism producing 5'inosinic acid and process for producing 5'inosinic acid using this
NO993119L (en) Material containing poly-reaction products and process for making the same
DK1000154T3 (en) Identification of human cell lines for production of human proteins by endogenous gene activation
DE69931807D1 (en) PREPARATION OF ASCORBIC ACID USING YEAST
BR0001342A (en) Process for the production of l-amino acids by fermentation using corineform bacteria
MXPA02012376A (en) Method for producing 5-aminosalicyclic acid.
EP1182184A4 (en) Process for producing tetrafluoro benzenemethanols
CA2191407A1 (en) Process for using the yeast adh ii promoter system for the biotechnological production of heterologous proteins in high yields
ATE413451T1 (en) METHODS FOR MASS CULTIVATION OF CELLS THAT PRODUCE RECOMBINANT HUMAN ERYTHROPOIETIN
DK1091001T3 (en) Process for the purification of S-adenosyl-L-methionine and for the preparation of pharmaceutically acceptable salts thereof
EP0233733A3 (en) Process for producing n-phthaloyl-p-nitro-l-phenylalanine
DK1001929T3 (en) Process for the preparation of 3-cyano-2,4-dihalo-5-fluoro-benzoic acids
DK288489D0 (en) PROCEDURE FOR THE PREPARATION OF 4-CHLOR-3-ALCOXY-BUT-2E-ONE-ACID COOLESTERS